According to several studies published from 2010 to 2015 (one meta-analysis study and four clinical studies) [32–36], about 50–86% of AML patients with IDH mutations achieved CR after other treatment schemes, and the 2-year OS rate was about 35–55%. Here, IDH1 is linked to acute myeloid leukemia.